The Traderszone Network

Most Sector Leaders have run up well out of buy range, and Ulta Beauty (ULTA) is no exception.

Shares are far extended beyond a 188.58 buy point cleared March 11 in heavy volume. Even though the stock hasn’t shown clear signs of slowing down, investors who bought at the breakout should consider taking some profits, since most stocks will pause to digest gains following a 20% to 25% run-up.

read more

Bullish traders are mostly cheering a recent rise in energy prices, but one sector among the S&P 500’s 10 isn’t eager to laud the re-emergence of higher oil: telecom.
read more

The Kumin family will not go hungry.

Deutsche Bank thinks the Fed could pull it off
From Deutsche Bank:
Has the Fed bought ‘optionality’ on the September meeting? If buying ‘optionality’ involves raising the market expectations of a rate rise to the point where the Fed can if desired raise rates without significantly surprising the market then at least based off fed fund futures, so far this has been a failure.

In a rerun of last summer’s political interference in pharmaceutical pricing spearheaded by both Bernie Sanders and Hillary Clinton, which initially focused on Martin Shrekli’s price hike of the Turing Pharmaceuticals Daraprim drug, then shifted to Allergan (and everyone knows what happened after), over the past few days much of the media’s attention has focused on the ongoing cost increases of Mylan’s Epipen.

read more

The median stock trades at the 99th percentile of its historical valuation. Here’s what that means to your portfolio.

This article is published in collaboration with Scutify, where you can
find real-time markets a